Neuroprotection in newborns. Review of current evidence

Abstract

Neonatal hypoxia / ischemia increases morbidity and mortality, influences the further development of the child. This review presents current evidence of the effect of some substances with supposedly neuroprotective properties on the outcomes of newborn with perinatal encephalopathy. The results of the different temperature regimes after intranatal asphyxia are discussed. In previous trials, the efficacy and safety of therapeutic hypothermi a has been proven. Its use is enshrined in international recommendations on cardiop ulmonary resuscitation. However, in recent studies, no difference in outcomes is observed with the use of therapeutic hypothermia in comparison with normothermia. Evidence of the effect on the further neurological development the use in the early neonatal period of recombinant human erythropoietin in neonates with perinatal asphyxia is presented. Based on the results of the first randomized controlled trial, the use of xenon in combination with hypothermia did not lead to better outcomes than hypothermia alone. Data are given on the effect of caffeine citrate on the further neurological devel opment of children who received a drug for the treatment of apnea of prematurity in the neonatal period.